Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome.
In women with polycystic ovary syndrome, chromium picolinate (200 microg/d) improves glucose tolerance compared with placebo but does not improve ovulatory frequency or hormonal parameters. This pilot study indicates that future studies in the polycystic ovary syndrome population should examine higher dosages or longer durations of treatment.
Lucidi
R Scott
RS
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, Texas 78229, USA. scott.lucidi@us.army.mil
Thyer
Angela C
AC
Easton
Carol A
CA
Holden
Alan E C
AE
Schenken
Robert S
RS
Brzyski
Robert G
RG
D000293:Adolescent; D000328:Adult; D005260:Female; D018149:Glucose Intolerance / Q000188:drug therapy; D006801:Humans; D007333:Insulin Resistance; D007502:Iron Chelating Agents / Q000008:administration & dosage*; D008597:Menstrual Cycle / Q000187:drug effects*; D010053:Ovary / Q000502:physiology; D010060:Ovulation / Q000187:drug effects; D010848:Picolinic Acids / Q000008:administration & dosage*; D010865:Pilot Projects; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000503:physiopathology
D007502:Iron Chelating Agents; D010848:Picolinic Acids; C030614:picolinic acid